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Background: Bone remodeling in calciﬁed aortic valves is thought to originate frommicrofractures at multiple
sites of the valve, at which osteoclasts and osteoblasts are recruited. The aim of the present study was to as-
sess circulating mediators of bone homeostasis, correlate them to the severity of stenosis and explore the
spatio-temporal distribution of bone turnover in different parts of calciﬁed aortic valve tissue.
Methods and results: Plasma and explanted aortic valves were obtained from 46 patients undergoing aortic valve
replacement surgery. Plasma levels of tartrate-resistant acid phosphatase (TRAP), receptor activator of nuclear-κB
(RANK) ligand and Runt-related transcription factor 2 (Runx2/Cbfa1) exhibited a signiﬁcant correlation to the se-
verity of aortic stenosis. mRNA levels in normal, thickened and calciﬁed parts of aortic valves assessed by quanti-
tative real-time PCR were signiﬁcantly elevated in calciﬁed parts of valves for TRAP (5.08±1.6-fold, Pb0.001)
RANK ligand (8.6±4.2-fold, Pb0.001) and RANK (1.98±0.78-fold, P=0.015). In an age, gender and aortic valve
anatomy-adjusted multivariable regression analysis the local transcript levels of TRAP correlated signiﬁcantly
with echocardiographic parameters quantifying stenosis severity in early stages, whereas the expression level of
Runx2/Cbfa1 was a predictor of the stenosis severity in advanced stages.
Conclusions: These ﬁndings suggest a critical role of bone turnover as a determinant of aortic stenosis severity.© 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
In aortic stenosis, the intact well-functioning aortic valve is
transformed into thickened tissue containing dystrophic calciﬁca-
tion, microfactures, apoptotic cores and lamellar bone [1–5]. His-
topathologically, the early phase demonstrates valvular thickening
characterized by inﬂammation [6], disruption of the basement mem-
brane, inﬂammation-associated punctuate calciﬁcations [7] and the
presence of extra-and intracellular lipids [8,9]. In end-stage disease het-
erotopic bone formation takes place, which is an actively regulated form
of bone formation resembling that in skeletal bone [1]. However, where-
as heterotopic bone formation contributes to local valvular calciﬁcation
[1,12], dystrophic calciﬁcation appear to be the dominating mechanism
in heavily calciﬁed aortic valves. Importantly, the extent of aortic-valveported by the Swedish Research
Wiberg's Foundation. AFC was
icine, CMM L8:03, Karolinska
r CC BY-NC-ND license.calciﬁcation is an independent predictor of outcome [10] and correlates
signiﬁcantly with stenosis severity [11].
Valvular insterstitial cells (VIC), a heterogenous cell population re-
siding in the interstitial layer of the aortic valve are responsible for the
maintenance of valve integrity and support the intact valvular architec-
ture. Under pathological conditions, a subset of these cells undergoes
phenotypic transdifferentiation toward bone-producing osteoblast-
like cells displaying expression of osteogenic markers [3,13,14]. This
phenotypic plasticity may involve epigenetic regulation [15]. De-
scriptive studies demonstrated upregulation of molecular calciﬁcation
markers in aortic valve tissue including Runt-related transcription
factor 2 (Runx2/Cbfa1), a central transcriptional regulator of
osteoblastogenesis, osteocalcin (BGLAP) [13] and bone morpho-
genetic protein-2(BMP-2) [16].
In addition, the active inﬂuence of receptor activator of nuclear-κB
ligand/receptor activator of nuclear-κB/osteoprotegerin (RANKL/RANK/
OPG-axis), which regulates osteoclast differentiation [17], activation
and survival [18,19], has also been suggested to inﬂuence aortic stenosis.
Osteoclasts are of hematopoietic origin as part of the monocytic lineage.
In the context of skeletal bone formation, an osteoblast–osteoclast
crosstalk has been described [18], demonstrating regulatory effects
of osteoblasts on the recruitment and activity of osteoclasts, which
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(BMU). This unit works as a spatially and temporally controlled team
of bone-resorbing osteoclasts and bone-forming osteoblasts [20] in re-
sponse to regulatory cytokines, such as RANKL that can bind either to
its receptor, RANK, or to a soluble competitive RANK inhibitor, OPG,
both of which are members of the TNF receptor superfamily [18]. Once
RANKL binds to RANK on the osteoclasts a series of events stimulate
bone resorption and extracellular matrix (ECM) degradation though
activity of cysteine proteases, matrix metalloproteinases (MMP) and
osteopontin phosphatase. The latter enzyme, also known as tartrate
resistant acid phosphatase (TRAP), is also a generator of reactive ox-
ygen species (ROS) [19]. In the inﬂammatory process of aortic valve
stenosis [21], oxidative stress [22], dystrophic calciﬁcation, hetero-
topic ossiﬁcation and ECM remodeling [7] all participate in the he-
modynamic progression of stenosis severity. Bone remodeling in
calciﬁed aortic valves is thought to originate from microfractures
caused by hemodynamic strain at multiple sites of the valve [1],
and both osteoclasts and osteoblasts have been detected in stenotic
aortic valves [5,7,13]. However, the relative importance of these
constituents of the BMU in the context of aortic stenosis remains
to be established.
The aim of the present study was to elucidate the association be-
tween circulating levels and local valvular expression levels for medi-
ators of bone turnover with echocardiographic measures of aortic
valve calciﬁcation and aortic stenosis severity.
2. Methods
2.1. Patients
The study consisted of 46 patients undergoing aortic valve replacement surgery for
aortic stenosis with either bicuspid or tricuspid anatomy, without concomitant signif-
icant obstructive coronary artery disease or no history of rheumatic heart disease. The
study was approved by the local ethics committee (Reference 2008/630-32), and all
patients gave informed consent. An extensive description of patient population and
study design has been presented elsewhere [21].
2.2. Echocardiography
Preoperatively (usually within a month before operation), all patients underwent
two-dimensional transthoracic Doppler echocardiography using a Philips IE33 system
(Philips Medical Systems, Andover, MA). The severity of aortic valve stenosis was based
on 1) the aortic valve area (AVA, cm2) calculated using the continuity equation, 2) AVA
indexed for body surface area (AVA/BSA, cm2/m2), 3) the ratio of the systolic time velocity
integral (VTI) in the left ventricle outﬂow tract to the VTI in the aortic valve, and 4) the
mean transvalvular pressure gradient (P-mean, mm Hg) according to the current guide-
lines [23,24]. The left ventricular geometry and function, and aortic root dimensions
weremeasured according to the recommendations of the American Society of Echocardi-
ography [25]. The echocardiographic assessment of the aortic valve anatomy as bicuspid
or tricuspid was conﬁrmed intraoperatively. Based on the echocardiographic assessment,
the study population was categorized into 2 groups: isolated, severe aortic stenosis with
either a 1) bicuspid, n=23 or a 2) tricuspid, n=23 valve anatomy.
2.3. Echocardiographic aortic valve calciﬁcation (AVC) scoring
In real time short-axis (SAX) view an overall calcium score (from 1 to 5) was
assigned as 1: normal leaﬂets, 2: thickened with no evidence of calciﬁcation, 3: mild
calciﬁcation (b1/3 of leaﬂet area), 4: moderate calciﬁcation (1/3-2/3 of leaﬂet area)
and 5: severe calciﬁcation (>2/3 leaﬂet area) [26].
2.4. Sample preparation and macroscopic dissection
Immediately after surgical removal, valves were immersed in RNA Later (Qiagen)
and stored at 4 °C until transport to the laboratory. Before careful macroscopic dissec-
tion was performed, whereby each individual cusp was divided in the RNA Later solu-
tion into: 1) normal areas deﬁned as non-calciﬁed, smooth, pliable, and opalescent; 2)
thickened areas; and 3) calciﬁed areas. From each class, 1 sample from each cusp was
frozen at −80 °C until RNA extraction. The macroscopic deﬁnitions were veriﬁed by
histology in a subset of preparations (n=89) using eosin and hematoxylin, Masson
trichrome and Alizarin red, as previously described [21].
2.5. RNA extraction and quality assessment
Total RNA was isolated from 190 preparations from 46 patients, representing the
various portions (normal, thickened, and calciﬁed) from each aortic valve cusp, usingthe RNeasy Lipid Tissue Mini kit (Qiagen). RNA concentrations were measured spectro-
photometrically at 260 nm (A260/280 nm, Agilent Technologies, Palo Alto, CA). Then,
the quality of the RNA was analyzed on a 2100 Bioanalyzer (Agilent, Palo Alto, CA,
USA) using RNA 6000 NANO chips to assess the RNA Integrity Number (RIN), as de-
scribed [27].
In total, the gene expression data for 190 preparations from 46 patients were used
for further analysis. On average, 4 preparations were examined for each aortic valve. In
subsequent analyses, a mean value of each tissue category (i.e. normal, thickened, and
calciﬁed, respectively) was calculated for each individual. The number of tissue sam-
ples included in normal group (demonstrated in Figs. 2 and 3 respectively) were 29
samples, since not every valve contained macroscopically normal part of the valvular
tissue. In the thickened group 62 samples and in the calciﬁed group 96 tissue samples
were included, respectively.2.6. TaqMan real-time PCR
First-strand cDNA was synthesized from 0.5 μg RNA (Superscript II, Invitrogen,
Carlsbad, CA) with random hexamers according to the manufacturer's instructions.
Quantitative TaqMan PCR was performed on a 7900HT Fast Real-Time PCR system
(Applied Biosystems) with primer/probe pairs that were obtained using Assay-on-
demand™ from Applied Biosystems (Cyclophilin A=PPIA: Hs99999904_m1; BGLAP:
Hs01587813_g1; BMP-2: Hs01055564_m1; BMP-6: Hs01099594_m1; Runx2/Cbfa1:
Hs00231692_m1; TNFSF11=OPG: Hs00243522_m1; TRAP: Hs00356261_m1; SPP1:
Hs00959019_m1; RANK: Hs00187192_m1; RANKL: Hs002433522_m1); the reactions
contained 5 μl cDNA that was diluted to 1.5 ng/μl and 5 μl TaqMan™ Fast Universal PCR
Master Mix (Applied Biosystems, Foster City, USA). Levels of mRNA were normalized to
expression levels of Cyclophilin A, which previously has been determined as an appropri-
ate housekeeping gene in these cells [21].2.7. Blood sample collection
Preoperatively, blood was drawn from an antecubital vein into EDTA tubes from all
the patients included in the present study, put on ice and centrifuged within 30 min.
Plasma was stored at −80 °C until analysis of bone-related circulating biomarkers.
Serum creatinine, lipid proﬁle, HbA1c, and high sensitive CRP were measured using
well-established methods routinely used in clinical practice.2.8. Enzyme immunoassays
Plasma concentrations of human total OPG, MMP-9 (R&D Systems, Minneapolis,
MN, USA), BMP-2 (Boster Immunoleader, Fremont, CA, USA), BMP-6, BGLAP, RANK,
Runx2, TRAP (USCN Life Science Inc., Wuhan, China), OPN (Ray Biotech, Parkway
Lane, USA), and RANKL (BioVendor Research Diagnostic, Brno, Czech Republic) were
measured using commercially available ELISA kit. Each measurement was performed
according to the manufacturer's instructions. The intra-and interassay coefﬁcients of
variation were 2% and 7.9% respectively for MMP-9, b10% and b12% respectively for
BMP-6, BGLAP, RANK, Runx2, TRAP, OPN, OPG, 2.6% and 6.3% respectively for BMP-2,
and 8.7% and 9.15% respectively for RANKL.2.9. TRAP activity staining and immunoﬂuorescent staining
Transversal cryosections (10 μm thick) were cut, oriented from the cusp base to
the free edge, and ﬁxed in acetone. TRAP staining kit was used (Kamiya Biomedical
Company, Seattle, USA) according to the manufacturer's instruction. Immunoﬂuores-
cent stainings were performed using monoclonal mouse anti-human TRAP (Leica
microsystems) as primary antibody in calciﬁed part. Isotype-speciﬁc DyLight 594-
conjugated secondary antibodies (Vector) were used and the nuclei were counterstained
with 4′, 6-diamino-2-phenylindol (DAPI, Vector). Imageswere capturedwith confocalmi-
croscope (Leica DMI).2.10. Statistical methods; data analysis
Clinical parameters and gene expression data are expressed as medians and
ranges. After normality test (Shapiro–Wilk) and equality variance test, single compar-
isons were analyzed by t-test for clinical parameters, and Mann–Whitney U-test for
plasma measures and gene expression parameters. Correlations between quantitative
gene expression data and echocardiographic parameters were established by Spear-
man correlation. One way ANOVA was used for analysis of qPCR data (Figs. 2 and 3).
An age, gender and aortic valve anatomy adjusted multivariable regression analysis
was performed to evaluate gene expression parameters as predictors of the clinical ste-
nosis severity and in separate analysis circulating levels of biomarkers were assessed as
predictors to stenosis severity. A P-value b0.05 was considered signiﬁcant. A multiple
testing correction (FDR=false discovery rate) was carried out because of large number
of tests performed in the study. Analyses were performed using SigmaPlot version 11
(Systat Software, Inc.).
Table 1
Patient characteristics.
Aortic valve stenosis
All patients Bicuspid aortic valve Tricuspid aortic valve P-value
No. of patients 46 23 23
Male, n (%) 29 (63%) 16 (35%) 13 (28%)
Age, y 70.9 (28.5–87.1) 64.4 (28.5–82.4) * 76.2 (57.9–87.1) b0.001
BMI, kg/m2 26.9 (19.2–37.42) 26.9 (19.2–34.7) 26.3 (21.6–37.4) 0.682
Creatinine, (μmol/L) 78.5 (47–156) 76 (47–134) 79 (60–156) 0.235
HbA1c 4.5 (3–6.3) 4.5 (3.9–6.3) 4.5 (3–6.3) 0.659
t-cholesterol (mmol/L) 4.85 (2.7–6.7) 5 (2.7–6.7) 4.7 (3.3–6.1) 0.094
LDL-C (mmol/L) 2.9 (1.3–4.4) 3.05 (1.3–4.4) 1.8 (1.4–4.2) 0.26
HDL-C (mmol/L) 1.4 (0.5–2.9) 1.4 (0.5–2.9) 1.4 (0.6–2.5) 0.785
Triglyceride (mmol/L) 0.99 (0.38–13.8) 0.91 (0.42–13.8) 1.1 (0.38–3.7) 0.775
Hs CRP 1.35 (0.2–18) 1 (0.2–18) 1.5 (0.35–14.6) 0.59
AVA, cm2 0.73 (0.45–1.2) 0.76 (0.47–1.2) 0.72 (0.45–1) 0.134
AVA/BSA, cm2/m2 0.39 (0.26–0.6) 0.4 (0.3–0.6) 0.38 (0.25–0.58) 0.255
VTI-ratio 0.195 (0.14–0.37) 0.2 (0.16–0.28) 0.2 (0.14–0.37) 0.613
Aorta Vmax, m/s 4.475 (3.36–5.8) 4.5 (3.4–5.7) 4.5 (4–5.8) 0.255
P-mean, mm Hg 50 (27–93) 51 (27–85) 49 (37–93) 0.403
Left ventricular EF, % 61.9 (42–78) 61% (44–78) 64%(42–75) 0.55
LVEDD, mm 47 (36–63) 49 (36–63) 47 (37–57) 0.234
Overall calcium score 4 (3–5) 4 (4–5) 4 (3–5) 0.54
Statin users, % 18 (39.1%) 6 (13%) 12 (26%) 0.13
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3.1. Patient characteristics
Table 1 summarizes the clinical characteristics of the study cohort
demonstrating signiﬁcant differences between the ages of patients
with bicuspid (BAV) and tricuspid (TAV) valve anatomy. In addition,
two patients (one in BAV and one in TAV-group) had osteoporosis
and one patient (in TAV-group) was on oral calcium supplementation.
3.2. Biomarkers of mineralization correlate to stenosis severity and
valvular calciﬁcation
Plasma levels of OPG were signiﬁcantly higher in BAV patients,
whereas other circulating biomarkers were not signiﬁcantly different
between the groups (Table 2). Unadjusted analysis showed that plas-
ma levels of RANKL were signiﬁcantly correlated with P-max (r=
0.331, P=0.025), VTI-ratio (r=−0.426, P=0.0033), V-max (r=
0.327, P=0.027) and to P-mean (r=0.324, P=0.0284). In addition,
plasma levels of TRAP demonstrated positive correlation to the steno-
sis severity (P-max r=0.299, P=0.0463; P-mean r=0.324, P=0.03;
V-max r=0.305, P=0.0415).
The results of the age-, gender- and aortic valve anatomy adjust-
ed multivariable regression model are shown in Table 3, demon-
strating β-coefﬁcients. In this model, the plasma concentrations of
TRAP, Runx2/Cbfa1 and of RANKL were signiﬁcantly correlated with
P-max, P-mean, VTI-ratio, respectively (Table 3). In addition, ratios ofTable 2
Biomarkers measured in EDTA plasma.
Aortic valve stenosis
All patients Bicuspid aortic v
No. of patients 46 23
BMP-2 (pg/mL) 259.17 (46–1991) 251.5 (97.2–981
BMP-6 (pg/mL) Not detectable Not detectable
BGLAP(pg/mL) Not detectable Not detectable
Runx2 (ng/mL) 1.48 (0.052–109.3) 1.4 (0.052–16.2)
OPG (pg/mL) 2243.9 (1143.2–4753.5) 2502.7 (1735.8–
OPN (pg/mL) 43,840.8 (19,058.7–96,991.8) 43,772.6 (25,080
TRAP (ng/mL) 17.8 (6.26–205.52) 17 (9.1–149.8)
RANKL (pmol/L) 65.5 (29.4–264.8) 70 (29.4–264.8)
RANK (ng/mL) 2.8 (1.4–9.7) 3.1 (1.8–9.7)
MMP-9 (ng/mL) 58.4 (7.3–317.3) 57.2 (7.3–317.3)RANKL/RANK and RANKL/OPG were inversely associated with AVA/
BSA and VTI-ratio (Table 3). The plasma level for BMP-2was signiﬁcant-
ly correlated with the overall calcium score.
3.3. Histological analysis identiﬁes cells with osteoclastic properties in
stenotic valves
Given that themeasured biomarkers indicated an association of aor-
tic stenosis severity with the osteoclast activator RANKL and osteoclast-
derived TRAP,we determined the presence of osteoclasts in human aor-
tic valves. First, multinucleated cells were identiﬁed in close vicinity to
calcifying foci containing elements of lamellar bone (Fig. 1/A–D).
Second, TRAP positive cells were visualized through their activity
(Fig. 1/C). Third, immunoﬂuorescent staining revealed TRAP protein
expression in multinucleated cells of frozen sections from stenotic
aortic valves (Fig. 1/D).
3.4. Valvular expression of osteoblast and osteoclast markers
We next sought to determine the local valvular expression levels
of genes encoding markers of osteoblasts and osteoclasts in different
stages of aortic stenosis. mRNA levels of osteopontin (OPN) and
RANKL were signiﬁcantly higher in calciﬁed valve tissue compared
with normal and thickened areas (Fig. 2). BGLAP also exhibited a sig-
niﬁcant upregulation in calciﬁed tissue (not shown). However, mRNA
levels of BGLAP were low, and detected in only 21 of the 46 patients,
and BGLAP was therefore excluded from further analysis. In contrastalve Tricuspid aortic valve Overall P-value
23
.5) 271.4 (46–1991) 0.257
Not detectable
Not detectable
1.63 (0.21–109.3) 0.659
4753.5)* 2100.7 (1143.2–3817.5) 0.006
.7–96,991.8) 43,908.9 (19,058.7–73,779.3) 0.51
19.5 (6.26–205.5) 0.658
64.66 (36.26–122.34) 0.496
2.2 (1.37–6.4) 0.069
71.2 (16.1–214.1) 0.93
Table 3
Multivariable regression, adjusted for age, gender and aortic valve anatomy for log-transformed circulating biomarkers. Beta-coefﬁcients are shown. *Pb0.05; **Pb0.01.
Runx2/Cbfa1 BMP-2 TRAP MMP-9 RANKL RANK RANKL/OPG RANKL/RANK
AVA/BSA, cm2/m2 0.016 0.026 0.017 0.021 −0.06* 0.063 −0.047* −0.051*
AVA, cm2 0.014 0.004 0.012 0.036 −0.066 0.075 −0.06 −0.062
P-max, mm Hg 4.62* 8.67 10.4* −0.46 11.3 5.64 2.92 3.12
P-mean, mm Hg 3.28* 5.39 7.86* −1.61 7.5 4.2 1.93 1.9
VTI-ratio 0.017 0.03 0.037 0.054 −0.15* 0.041 −0.13* −0.09
Overall calcium score 0.015 0.072** 0.028 0.02 0.02 −0.03 0.02 0.02
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were similar in all types of valvular tissue (Fig. 2). mRNA levels for OPG
showed a tendency toward higher expression values in the calciﬁed
parts, although these changes did not reach statistical signiﬁcance
(Fig. 2).
Genes taking part in osteoclast differentiation, activation and sur-
vival, such as RANKL, RANK and TRAP exhibited gradually increased
expression levels with the most abundant expression in the calciﬁed
part of the valve (Fig. 3). Congruent with these observations, the
RANKL/OPG and RANKL/RANK ratios were signiﬁcantly higher in
the calciﬁed parts (Fig. 3).Fig. 1. A: Overview of calciﬁed part of aortic valve demonstrating 1: cartilaginous nodule in c
*; 2: mature lamellar bone with active osteoclastic resorption, original magniﬁcation 20×. B:
valve. Hematoxylin and eosin, original magniﬁcation 40×; C: light microscopy of TRAP activ
original magniﬁcation 10×. D: immunoﬂuorescent staining for TRAP counterstained with D3.5. Correlations of genes involved in osteogenesis and osteoclast activity
in different stages of valvular stenosis/different parts of stenotic valves
Since the three valvular tissues (healthy, thickened and calciﬁed)may
represent different stages of aortic stenosis, we next determined the cor-
relations of the expression levels of osteoblast- and osteoclast-associated
genes during disease progression (Fig. 4). In the calciﬁed parts the tran-
script levels for Run2/Cbfa1, a central transcriptional regulator of osteo-
blasts, demonstrated signiﬁcant correlations with the transcript levels
for BMP-2, and-6, potent osteogenic morphogenes, as well as with OPG,
a regulatory cytokinewith a control function in osteoclast differentiation.lose vicinity to atheromatous plaque containing dystrophic calciﬁcation, indicated as an
osteoclast sitting in a Howship's lacuna/resorption space within a calciﬁed part of aortic
ity staining identiﬁes an area with strong TRAP activity in close vicinity to calciﬁcation,
API demonstrates multinucleated cells, as arrows indicate.
Fig. 2. Relative gene expression data (normalized for the normal area obtained from the stenotic aortic valve cusp) for OPN, RANKL, BMP-2, Runx2/Cbfa1, BMP-6, and for
OPG.*Pb0.05 considered statistically signiﬁcant.
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positive correlations existed between mRNA levels for CD 68, TRAP, and
for MMP-9 corroborating previous ﬁndings on the hematopoietic origin
of osteoclasts (Fig. 4). Genes responsible for osteoblast activity and
those taking part in osteoclast differentiation, were positively correlated
in end-stage valvular disease.
Similar univariate correlation analyses were performed in the nor-
mal part of the valvular tissue and showed inverse correlations be-
tween BMP-6 and TRAP, BMP-6 and MMP-9, Runx2/Cbfa1 and TRAP
and Runx2/Cbfa1 and MMP-9, respectively (Fig. 4). In contrast, thick-
ened areas of the stenotic valves (Fig. 4) demonstrated positive corre-
lations between genes responsible for osteoblast differentiation and
activity and genes taking part in the osteoclast differentiation and ac-
tivity, similar to the situation observed in the calciﬁed parts of the
valves.3.6. Inverse correlations between gene expression with stenosis severity
and valvular calciﬁcation
Among the genes involved in osteoblast differentiation only
Runx2/Cbfa1 exhibited signiﬁcant association on the mRNA levelwith stenosis severity, with inverse correlations with AVA and BSA
indexed AVA both in the univariate analysis (data are not shown)
and in the age, gender and aortic valve anatomy-adjusted model
(β-coefﬁcient=−0.027; P=0.03) in the calciﬁed parts. In addition,
mRNA levels for TRAP in the normal part demonstrated inverse cor-
relation with AVA and AVA/BSA (β-coefﬁcient=−0.03, P=0.02;
β-coefﬁcient=−0.05, P=0.03, respectively).4. Discussion
The present study provides support for a role of osteoclasts in aor-
tic valve stenosis. Plasma levels of circulating TRAP and RANKL as well
as the RANKL/RANK and RANKL/OPG ratios were signiﬁcantly correlated
with the hemodynamic severity of aortic stenosis. These observations
were conﬁrmed at the tissue level by the enhanced transcriptional
proﬁle in calciﬁed valvular tissue of genes taking part in osteoclast
differentiation, activity and survival. In addition, circulating and local
levels of themaster transcription factor for terminal osteoblast differen-
tiation Runx2/Cbfa1 exhibited signiﬁcant correlation with the stenosis
severity. Taken together, these ﬁndings reveal a correlation between
gene expression programs involved in both osteoblast and osteoclast
Fig. 3. Relative gene expression data (normalized for the normal area obtained from the stenotic aortic valve cusp) for RANK, TRAP and for the ratios of RANKL/OPG and RANKL/
RANK.*Pb0.05 considered statistically signiﬁcant.
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plored mediators may have different clinical importance during dif-
ferent phases of disease development.
Only a few proteins associated with bone turnover have been ex-
plored as biomarkers of aortic stenosis. For example, some studies
showed that patients with aortic stenosis have higher levels of circu-
lating OPN [28–32] and OPG [33,34] compared with controls. In the
present study of aortic stenosis patients, neither of these two proteins
correlated with aortic stenosis severity, which corroborates another
study in which OPG was poorly correlated with the degree of aortic
stenosis [35]. In contrast, the present study identiﬁed Runx2/Cbfa1
as a predictor of aortic stenosis severity. Circulating levels of Runx2/
Cbfa1 have previously been shown to serve as biomarkers for the an-
abolic function of osteoblasts [36], and the present study demon-
strates for the ﬁrst time that plasma levels of this master osteogenic
transcription factor are associated with aortic stenosis. In addition,
given that the extent and distribution of valvular calciﬁcation is an inde-
pendent predictor of clinical outcome in aortic stenosis [10], it is interest-
ing that plasma levels of BMP-2 were correlated with echocardiographic
overall calcium score in the present study. Taken together, these ﬁnd-
ings suggest that systemic levels of osteoinductive biomarkers, such as
Runx2/Cbfa1 and BMP-2 may reﬂect aortic stenosis and calciﬁcation.
Interestingly, plasma measures of mediators associated with osteo-
clastic differentiation (RANKL, and the ratios of RANKL/OPG, RANKL/
RANK) and activity (TRAP) correlated with hemodynamic measures of
stenosis severity, providing a ﬁrst indication that osteoclast-derived
biomarkers are associated with aortic stenosis. Histological analysis
conﬁrmed the presence and activity of osteoclasts, localized in close
proximity to calcifying foci containing elements of mature lamellar
bone in human stenotic aortic valves.
To explore whether the association of circulating osteoclast
markers with stenosis severity reﬂected a local process in the valve
we next explored gene expression levels of these osteoclast markers
in human aortic valves. Interestingly, all examined genes related
to osteoclast differentiation and activity exhibited a signiﬁcantly
upregulated transcriptional proﬁle in end-stage calciﬁed aortic valvetissue. In addition, the local expression of TRAP, an enzyme with strong
proteolytic activity, was associated with stenosis severity in the early
stages of the disease.
Previous observations on the role of osteoclasts in the context of aor-
tic stenosis have generated contradictory results. For example, one study
suggested that the bone resorptive activity of osteoclasts may reduce the
mineral content of the valve and lead to hemodynamic retardation [37].
In contrast to that notion, several retrospective analysis demonstrating
positive hemodynamic effects on aortic stenosis by osteoclast-inhibiting
bisphosphonates indicate that local induction of osteoclast apoptosis in
the calciﬁed aortic valve may have a beneﬁcial effect [38–40]. However,
a recently published retrospective analysis investigating the role of
bisphosphonates on hemodynamic progression of aortic stenosis failed
to conﬁrm these ﬁndings [41].
The presence of osteoclasts in human aortic valves, the upregulation
of osteoclasts in calciﬁed valve tissue and the association of both circu-
lating levels and local osteoclast markers with stenosis severity in the
present study may suggest a role for osteoclasts in aortic valve stenosis.
The potential mechanism through which osteoclasts could participate
in aortic stenosis progression may be through the catalytic activity of
enzymes leading to valvular remodeling. In support of this suggestion,
our data demonstrate, for the ﬁrst time, an association between both
circulating and tissue levels of TRAPwith aortic stenosis. In addition, os-
teoclasts are a source ofMMP-9 and Cathepsin K, which previously have
been implicated in valvular calciﬁcation [21,42,43]. This notion that os-
teoclasts paradoxically may increase valvular calciﬁcation has received
support from experimental studies, showing that cardiovascular calciﬁ-
cation inversely correlateswith bone tissuemineral density in hyperlip-
idemic mice [44].
To better understand the interaction between osteogenic and
osteoresorptive pathways and their role during different stages of
aortic stenosis, we compared gene expression levels of osteoblast
and osteoclast markers in human aortic valves. The increased numbers
of positive correlations as the valve tissue progressed from normal
through thickened to calciﬁed suggest that active bone turnover and
BMU formation is accelerated at later stages of aortic stenosis. However,
Fig. 4. Results of correlations analysis between genes of bone homeostasis in different parts of aortic valve tissue. A scale bar indicates color-coded correlations coefﬁcients. Ns in-
dicates non signiﬁcant results.
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was in contrast to previously reported differential mRNA expression
of thesemediators in calciﬁed human aortic valves compared with con-
trols [13], and suggests that the valvular interstitial cells within normal
tissue of diseased valves may have started to undergo osteoblastic
transdifferentiation [12,45]. In addition, the inﬂammatory environment
and increased levels of ROSwithin the affected valvular tissuemay have
harmful effects on osteoblastic functions [46]. Nevertheless, in coher-
ence with the biomarker data, transcription levels of Runx2/Cbfa1 in
calciﬁed areas correlated with stenosis severity, which indicates that
both systemic and tissue levels of Runx2/Cbfa1 were consistently relat-
ed to hemodynamic progression.
OPN, which in addition to anti-calciﬁc actions also may exert pro-
inﬂammatory effects through its N-half liberated by thrombin cleavage
[47], was upregulated in calciﬁed valvular tissue in the present study. In
human aortic valves, OPN has previously been associated with mainly
macrophage accumulation anddystrophic calciﬁcation [48], and the pres-
ent ﬁndings hence corroborate our previous results on upregulated ex-
pression of macrophage markers and the leukotriene pathway [21].
The present study allowed sampling of several osteoblast- and os-
teoclast associated mediators at both the systemic and tissue levels,and their association with aortic stenosis. Several limitations should
however be acknowledged. For example, the present study is a single
center study limited to aortic stenosis patients (small sample size),
with the aim to associate the explored mediators to clinical param-
eters of stenosis severity. Nevertheless, our previous study showed
that healthy tissues within stenotic valves are an appropriate control
tissue [21]. It should also be acknowledged that multiple univariate
associations were performed and that modest testing corrections
through FDR resulted in somewhat lower experiment-wise signiﬁ-
cance levels compared with those obtained in individual analysis.
The measured mediators should therefore not be interpreted as po-
tential biomarkers for predicting aortic stenosis severity, but rather
for their potential mechanistic involvement in the pathophysiology,
which was then further explored at a tissue level. Finally, these me-
diators are not solely expressed in aortic valves, and it cannot be ex-
cluded that circulating levels are at least in part derived from other
sources, such as skeletal bone and undiagnosed bone disease.
In conclusion, the present study highlights a correlation between
genes with osteoinductive and osteoresorptive functions and stenosis
severity under in vivo disease development. Whereas the expression
levels of genes involved in active bone formationwere unaltered during
2271E. Nagy et al. / International Journal of Cardiology 168 (2013) 2264–2271the disease course, the end-stage was characterized by increased os-
teoclastic activity with potential structural, morphological and he-
modynamic consequences. The associations between systemic levels
of Runx2/Cbfa1, RANKL, TRAP and stenosis severity highlight their crit-
ical role for stenosis development and offers novel insights into the
pathogenesis of aortic valvular disease in man.
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